New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...
The Fort St. John Hospital Foundation has purchased a body plethysmograph, a vital piece of equipment for the respiratory ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Angina, a symptom of underlying heart disease, is frequently overlooked in women despite being a leading cause of death.
GSK plc announced plans to invest $30 billion in U.S. research and manufacturing over the next five years and entered a $500 million collaboration with Hengrui Pharma for drug development. The company ...
If men felt the way we do two weeks of the month, scientists would be working around the clock to solve their suffering. But ...
Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.
Adults with COPD receiving roflumilast had a smaller COPD exacerbation rate at 1 year vs. those receiving azithromycin but ...
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant ...
Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is introducing a suite of easy-to-use health plans and AI features for millions of people for 2026 open enrollment.“Choice is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback